Epigral Q3 FY26 results: Revenue Rs 597 cr, PAT Rs 39 cr YoY
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 0.7 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Epigral Q3 FY26 standalone revenue Rs 597.12 cr versus Rs 645.24 cr YoY, down about 7.5 percent. PAT fell to Rs 39.15 cr from Rs 103.54 cr, down 62 percent YoY. Nine months FY26 revenue Rs 1,791 cr versus Rs 1,922 cr; PAT Rs 251.08 cr boosted by a one-time Rs 80.87 cr deferred tax credit from opting for the lower Section 115BAA tax rate. Margins compressed sharply with finance costs up to Rs 10.95 cr. S R B C and Co LLP issued an unqualified limited review.
Revenue and profits fell sharply YoY with margin compression; sequential revenue improved but PAT slipped QoQ. Watch chlor-alkali demand recovery.